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The	pathology	of	 the	 thyroid	gland	presents	 the	
pathologist	with	a	set	of	diagnostic	problems.	A	par-
ticular	problem	 is	distinguishing	between	 follicular	
thyroid	carcinoma,	 including	Hürthle	cell	 (oxyphilic	
or	oncocytic)	carcinoma	(HCC),	a	variant	of	follicular	
carcinoma,	and	 their	benign	counterparts,	 follicular	
thyroid	adenoma	and	Hürthle	cell	adenoma	 (HCA).	
These	 tumors	are	encapsulated,	and	 they	can	only	
be	distinguished	by	assessing	 the	 vascular	and/or	
capsular	invasion	on	histological	specimens.	It	is	gen-
erally	known	that	differential	diagnosis	is	often	difficult	
even	with	permanent	 sections.	Therefore,	 specific	
molecular	markers	to	discriminate	between	follicular	
thyroid	carcinomas	and	adenomas	in	thyroid	follicular	
lesions	are	needed.
One	possibly	suitable	molecular	marker	 to	 fulfill	
this	 role	 is	 thyroid	peroxidase	(TPO),	a	 thyroid-spe-
cific	enzyme	essential	for	the	biosynthesis	of	thyroid	
hormone.	In	the	last	few	years,	the	diagnostic	value	
of	TPO	 immunodetection	 in	 thyroid	neoplasms	has	
been	widely	discussed,	because	several	authors	have	
demonstrated	that	TPO	protein	is	expressed	in	benign	
tumors	and	normal	tissue	[1–3],	but	is	absent	or	poorly	
expressed	in	a	variety	of	thyroid	follicular	carcinomas	
[1,	 4–9].	 In	 addition,	 quantitative	 and	qualitative	
changes	in	TPO	activity	and	TPO	messenger	ribonu-
cleic	acid	(mRNA)	expression	have	been	reported	in	
pathological	thyroid	tissues	[10–16].
In	general,	 immunohistochemical	 studies	using	
mAb	47	have	shown	close	correlation	between	negativ-
ity	for	TPO	and	thyroid	carcinoma	malignancy	[1,	6,	8,	
13,	17].	These	findings	have	been	confirmed	in	studies	
on	FNA	samples	providing	sensitivities	between	97	and	
100%	for	overall	carcinomas	[4–6,	8].	However,	 the	
recent	studies	of	Lima	et	al.	[3],	Kholova	et	al.	[18,	19]	
and	Weber	et	al.	[20]	indicated	that	TPO	has	limited	
value	 in	 the	diagnosis	of	malignant	 follicular	 thyroid	
tumors.	Thus,	the	value	of	TPO	immunohistochemistry	
using	mAb	47	in	thyroid	carcinoma	diagnostics	is	still	
the	subject	for	discussion.
Disparate	results	in	the	literature	prompted	us	to	
explore	further	the	clinical	usefulness	of	TPO	staining	
for	the	differential	diagnosis	of	follicular	thyroid	carci-
noma	from	follicular	adenoma	of	the	thyroid.
MATERIALS AND METHODS 
Clinical and morphological data.	Formalin-fixed	
paraffin-embedded	tissue	sections	from	92	patients	
with	 follicular	 thyroid	 tumors	were	stained	 immuno-
histochemically.	Tissue	sections	were	obtained	from	
the	archival	material	of	the	Institute	of	Endocrinology,	
Diabetes	and	Metabolic	Diseases,	Clinical	Centre	of	
Serbia,	Belgrade.	Haematoxylin/eosin-stained	sec-
tions	from	each	sample	were	evaluated	histologically	
by	two	pathologists	to	classify	the	tumors	according	to	
the	World	Health	Organization	criteria	[21]	with	a	con-
sensus	diagnosis	being	reached	after	discussion	be-
tween	the	pathologists	when	a	disagreement	occurred.	
Consequently	 the	histological	 diagnoses	 in	 these	
patients	were:		28	cases	of	follicular	adenoma	(FTA),	
12	cases	of	follicular	adenoma	—	Hürthle	cell	variant	
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(HCA),	19	cases	of	follicular	thyroid	carcinoma	(FTC)	
and	33	cases	of	follicular	thyroid	carcinoma	—	Hürthle	
cell	variant	(HCC).	FTC	and	HCC	were	diagnosed	by	
the	presence	of	complete	capsular	and/or	vascular	
invasion,	and	the	absence	of	nuclear	features	of	papil-
lary	thyroid	carcinoma.	Hürthle	cell	carcinomas	were	
composed	of	greater	 than	75%	oncocytic	cells	with	
moderate	to	abundant	eosinophilic	granular	cytoplasm	
[22].	Fifteen	out	of	the	total	of	52	follicular	carcinomas	
were	defined	as	minimally	 invasive	 (10	Hürthle	cell	
carcinomas)	due	to	the	histological	finding	of	a	single	
focus	of	vascular	invasion,	a	single	focus	of	complete	
capsular	invasion,	or	both.
Immunohistochemistry.	Mouse	monoclonal	
antibody	against	 thyroid	peroxidase	 (TPO	mAb	47,	
Biocytex,	Switzerland)	was	employed	 for	 immunos-
taining	on	4–6	µm	thick	sections	using	the	avidin-biotin	
peroxidase	complex	 (ABC)	 technique	with	 reagents	
supplied	by	Vector	Laboratories	(Burlingame,	CA).
Following	deparaffination	and	 rehydration,	 en-
dogenous	peroxidase	activity	was	blocked	with	0.3%	
H2O2/methanol	followed	by	non-immune	horse	serum	
for	20	min	to	block	non-specific	binding.	The	sections	
were	 then	 incubated	with	primary	antibody	against	
TPO	at	4	˚C	overnight	at	a	dilution	of	1	:	50.	This	was	
followed	by	 incubation	with	biotinylated	horse	anti-
mouse	IgG	for	30	min	and	thereafter	with	the	avidin-
biotin-peroxidase	complex	(ABC	reagents)	for	30	min.	
Between	each	step,	sections	were	washed	three	times	
in	phosphate	buffered	saline	(PBS).		The	reaction	was	
visualized	using	3,	3΄-diaminobenzidine	 tetra	hydro-
chloride	(DAB)	solution.
After	 counterstaining	with	haematoxylin,	 slides	
were	dehydrated,	coverslipped	and	examined	using	a	
Reichart-Jung	microscope	supplied	with	a	Photostar	
automatic	camera	system.	Controls	were	 incubated	
with	PBS	in	place	of	the	primary	antibody	and	no	posi-
tive	staining	was	observed.	
Scoring of staining and statistical data. The	
percentage	of	positively	stained	cells	was	assessed	in	
a	semi	quantitative	fashion,	i.e.	the	following	system	
was	employed	 to	 score	 the	percentage	of	positive	
thyrocytes:	(0)	no	staining,	(1)	less	than	20%	positive	
cells,	 (2)	21	 to	50%	positive,	 (3)	51	 to	80%	positive	
and	 (4)	more	 than	80%	positive.	The	cut-off	 values	
proposed	by	De	Micco	et	al.	[4]	were	applied.	Thus,	
lesions	were	considered	positive	and	hence	allegedly	
benign,	if	more	than	80%	of	the	thyroid	epithelial	cells	
stained	for	TPO.	Tissue	staining	of	less	than	80%	of	the	
follicular	cells/specimen	was	considered	malignant.
The	sensitivity	was	defined	as	the	number	of	ma-
lignant	lesions	with	a	negative	TPO	staining	score	as	a	
fraction	of	the	total	number	of	true	malignancies.	
The	specificity	was	defined	as	the	number	of	true	
benign	lesions	with	a	positive	TPO	staining	score	as	a	
fraction	of	the	total	number	of	true	benign	lesions.	
Data	were	analyzed	with	the	Statgraphics	4.2	sta-
tistical	 software.	The	nonparametric	Mann-Whitney	
U-test	was	used	 to	determine	 the	 significance	of	
differences	between	groups.	A	value	P	<	0.05	was	
considered	to	be	statistically	significant.	
RESuLTS 
The	 results	of	 immunohistochemical	staining	 for	
TPO	protein	expression	in	tissue	sections	of	92	follicular	
tumors	are	summarized	in	the	Table.	The	19	FTC	showed	
great	variability	in	the	degree	and	intensity	of	staining.	
Thus,	virtual	absence	of	TPO	positivity	was	observed	
in	two	specimens,	while	ten	showed	weak	to	moder-
ate	cytoplasmic	positivity	with	more	than	20%	and	less	
than	80%	of	stained	cells,	but	seven	showed	positivity	
across	the	entire	section	(score	4).	Three	of	these	last	
seven	cases,	definitely	positive	for	TPO	staining,	were	
minimally	invasive	carcinomas,	but	the	remaining	four	
were	classified	as	widely	invasive	carcinomas.	
Table. Immunohistochemical detection of TPO expression in follicular 
thyroid tumors
Cut off     
Expression grade 0 1 2 3 4 Total
Malignant tumors
FTC 2 1 4 5 7 19
HCC 9 9 8 3 4 33
Total 11 10 12 8 11 52
Dg confirmed by TPO immunohistochemistry: 41/52 (79%)
Benign tumors
FTA 2 7 19 28
HCA 1 1 3 2 5 12
Total 1 1 5 9 24 40
Dg confirmed by TPO immunohistochemistry: 24/40 (60%)
Notes: FTC — follicular carcinoma; HCC — follicular carcinoma — Hürthle 
cell variant; FTA — follicular adenoma; HCA — follicular adenoma — Hürthle 
cell variant; Dg — diagnosis. The following system was employed to score 
the percentage of positive thyrocytes: (0) no staining, (1) 1 to 20% positive 
cells, (2) 21 to 50% positive, (3) 51 to 80% positive and (4) more than 80% 
positive. Tissue staining of more than 80% of the follicular cells/specimen was 
considered benign, less than 80% was considered malignant. FTC vs FTA 
P = 0.01; HCC vs HCA P = 0.012; total benign vs total malignant 
P < 0.0001.
Similar	variability	in	TPO	expression	was	also	noted	
for	oncocytic	epithelial	cells	in	HCC.	Namely,	virtual	ab-
sence	of	TPO	staining	was	observed	in	9/33	specimens,	
while	variable	positivity	occurred	in	the	remaining	cases.	
Two	of	four	HCC	cases	definitely	positive	for	TPO	were	
widely	invasive	carcinomas.	Thus,	the	number	of	TPO	
positive	cases	in	the	whole	carcinoma	group	was	11/52,	
which	means	 that	TPO	 immunohistochemistry	gave	
21%	false	negative	results	in	confirming	the	diagnosis	
of	follicular	cancer	(Table,	Figure,	c,	d).	The	sensitiv-
ity	of	TPO	 immunostaining	 for	FTC	and	for	HCC	was	
63	and	88%,	respectively,	with	an	average	sensitivity	
of	79%	for	both	types	of	carcinomas.	 In	addition,	no	
significant	difference	 in	TPO	underexpression	could	
be	established	between	minimally	invasive	and	widely	
invasive	carcinomas	(p	>	0.05).
Among	the	40	adenomas	24	cases	were	positive	
for	TPO	(including	five	cases	of	HCA)	showing	labe-
ling	across	the	entire	section	(Table,	Figure,	e,	f).	The	
remaining	nine	cases	of	FTA	and	seven	cases	of	HCA	
expressed	TPO	under	the	threshold	of	80%	positive	
thyrocytes	and	would	 therefore	be	considered	ma-
lignant	 from	 the	 immunostaining	 result	 (see	Table).	
The	specificity	of	TPO	 immunostaining	 for	FTA	and	
HCA	was	68	and	42%,	respectively,	with	an	average	
specificity	of	60%	 for	 the	whole	series	of	 follicular	
adenomas.	
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Thus,	TPO	underexpression	was	seen	in	a	signifi-
cantly	higher	number	of	FTC	cases	than	in	its	benign	
counterpart	(FTA)	(see	Table;	P	=	0.01).	Concerning	
Hürthle	 cell	 thyroid	 tumors,	 TPO	underexpression	
was	observed	in	88%	of	HCC	and	in	many	(58%)	HCA	
(P	=	0.01).	Thus,	 the	proportion	of	 immunoreactive	
cells	for	TPO	in	follicular	carcinomas	as	a	whole	was	
significantly	lower	than	that	observed	for	the	adeno-
mas	(P	<	0.0001).
DIScuSSION
Immunohistochemical	 investigations	of	 follicular	
thyroid	neoplasms	have	detected	many	molecular	
markers	for	follicular	carcinomas,	but	with	varying	de-
grees	of	sensitivity	and	specificity	for	these	neoplasms	
[23].		Among	the	molecular	markers	that	appeared	to	
yield	high	sensitivity	and	specificity	values	for	thyroid	
tumors	differential	diagnostics	was	TPO.	Thus,	several	
studies	using	mAb	47	for	the	immunohistochemical	de-
termination	of	TPO	indicated	that	it	may	be	a	potentially	
important	diagnostic	tool	for	thyroid	cancer	[1,	4,	6,	8,	
17,	24,	25].	However,	some	later	results	showed	disa-
greement	between	mAb	47	findings	and	the	histological	
diagnosis	of	follicular	tumors	[3,	18,	19,	20].
In	this	study,	we	focused	on	the	utility	of	TPO	im-
munostaining	using	mAb	47	as	a	tool	for	distinguishing	
between	 follicular	 thyroid	adenoma	and	carcinoma,	
figure.	Immunohistochemical	staining	for	thyroid	peroxidase	(TPO)	in	follicular	thyroid	carcinoma	and	follicular	thyroid	adenoma	
(indirect	 immunoperoxidase	 technique;	 hematoxylin	 diaminobenzidine	 counterstaining).	 (a):	 FTC	case	 showing	negative	
immunostaining	for	TPO	(right)	which	confirms	the	malignant	nature	of	the	lesion	and	TPO	positivity	in	nonmalignant	surraunding	
tissue	(left).	(b):	Complete	TPO	immunonegativity	in	one	case	of	HCC.	(c):	Positive	TPO	staining	in	a	case	of	widely	invasive	FTC	failed	
to	confirm	the	diagnosis.	(d):	Widely	invasive	HCC	expressing	TPO	in	more	than	80%	of	thyrocytes.	(e):	Characteristic	positive	TPO	
immunostaining	in	FTA	indicating	a	benign	thyroid	tumor.	(f): HCA	showing	strong	cytoplasmic	immunopositivity	for	TPO	present	
throughout	the	whole	section	which	confirms	the	benign	nature	of	the	lesion	(Original	magnification	a, c, e	x	10	and		b, d, f x	20)
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including	the	Hürthle	cell	type.	The	results	showed	that	
TPO	immunostaining	correlated	with	the	histopatho-
logical	diagnosis	in	24/40	cases	of	follicular	adenomas	
giving	a	specificity	of	60%.	On	 the	other	hand,	ma-
lignancy	was	correctly	 identified	in	41	of	52	patients	
with	 follicular	carcinomas,	giving	sensitivity	of	79%.	
This	 is	a	higher	 incidence	of	TPO	false-positivity	for	
follicular	cancer	 than	previously	observed	 in	 some	
studies	[1,	4–6],	but	lower	than	reported	by	other	au-
thors	[3,	20]	with	the	same	antibody	and	methodology.	
Namely,	in	Lima’s	series	of	follicular	neoplasms	with	
the	same	threshold	for	positivity	applied	(80%),	it	was	
noted	that	46.2	%	of	the	follicular	thyroid	carcinomas	
were	of	dismissed	diagnosis	[3].	Recently,	Weber	et	
al.	[20]	reported	TPO	staining	sensitivity	of	only	11%	
for	follicular	thyroid	carcinoma	with	a	different	thresh-
old	(less	than	5%	of	follicular	cells	staining	positively	
for	TPO	considered	malignant).	Moreover,	 variable	
expression	of	TPO	was	described	in	benign	follicular	
adenomas,	with	specificity	 ranging	 from	68	 to	96%	
[4,	18].	De	Micco	et	al.	[4]	found	that	the	specificity	of	
TPO	staining	was	greater	in	microfollicular	adenomas	
(83.3%)	 than	 in	oncocytic	nodules	 (47.1%).	 In	our	
series	of	adenomas,	specificity	for	TPO	protein	in	FTA	
was	also	higher	(68%)	than	in	HCA	(42%),	indicating	a	
difference	between	these	two	types	of	benign	tumors.	
Thus,	in	confirmation	of	the	findings	of	De	Micco	et	al.	
[4]	and	Faroux	et	al.	[6],	the	practical	role	of	TPO	as	a	
marker	in	Hürthle	cell	tumors	may	be	questioned	by	
its	low	specificity.	
Evidence	from	earlier	reports	 indicated	that	TPO	
protein	is	frequently	underexpressed	in	human	differ-
entiated	cancers	and	is	particularly	poorly	expressed	
in	more	malignant	and	dedifferentiated	tumor	lesions	
[6,	11,	17].	Thus,	no	TPO	expression	was	 found	 in	
anaplastic	 thyroid	carcinoma,	 the	most	aggressive	
thyroid	cancer	representing	the	last	stage	of	thyroid	
epithelium	dedifferentiation	 [3,	6,	26].	 	 In	addition,	
Weber	et	al.	[20]	found	some	evidence	that	the	lack	
of	expression	of	TPO	in	papillary	cancer	might	predict	
a	worse	clinical	outcome.
In	our	study,	no	 relationship	was	 found	between	
TPO	staining	and	the	type	of	invasion	in	follicular	car-
cinomas,	because	the	widely	 invasive	type,	a	highly	
aggressive	malignancy,	was	not	necessarily	negative	
(see	Figure	c,	d).	We	 therefore	 failed	 to	establish	a	
significant	decrease	in	TPO	protein	expression	in	fol-
licular	carcinoma	with	higher	aggressiveness.	
In	summary,	from	our	evaluation	of	the	utility	of	TPO	
immunostaining,	we	conclude	that	the	clinical	use	of	
this	marker	has	limited	diagnostic	value	and	that	the	
distinction	between	 follicular	 thyroid	adenoma	and	
follicular	thyroid	carcinoma	should	be	primarily	based	
on	classical	histological	criteria.
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Эффективность использования пероксидазы 
в качестве маркера для определения различий между 
фолликулярной карциномой и фолликулярной 
аденомой щитовидной железы
Цель: уровень экспрессии тироидной пероксидазы (ТПО) в ткани щитовидной железы является чувствительным мар-
кером малигнизации этого органа. В работе  представлено попытку оценки метода иммуногистохимический детекции 
ТПО для дифференциальной диагностики фолликулярной карциномы и фолликулярной аденомы щитовидной железы 
(ФКЩЖ и ФАЩЖ соответственно). Материалы и методы: срезы ткани, зафиксированные в формалине, были получены 
у 92 пациентов с опухолями щитовидной железы (52 случая — ФКЩЖ и 40 — ФАЩЖ, в том числе тип с клетками Хюрт-
ля). Для иммуногистохимического анализа этих срезов использовали моноклональные антитела против ТПО (ТРОmAb47) 
и авидин-биотиновый комплекс. Препараты опухолей, содержащих более 80% позитивно окрашенных фолликулярных 
клеток, признавали доброкачественными, а те, что содержали менее 80% таких клеток, — злокачественными. Результа-
ты: интенсивность иммуноокрашивания препаратов коррелировала с гистопатологическим диагнозом в 24 из 40 случаев 
ФАЩЖ и в 41 из 52 случаев ФКЩЖ. При этом чувствительность метода составляла 79%,  специфичность — 60%. 
Выводы: иммуногистохимический анализ ТПО имеет недостаточную специфичность для дифференциальной диагностики 
фолликулярной карциномы и фолликулярной аденомы. 
Ключевые слова: щитовидная железа, фолликулярная карцинома щитовидной железы, тироидная пероксидаза, молекулярный 
маркер, иммуногистохимия.
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